HARROW INC (HROW)

Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery

Harrow Announces Participation in Upcoming Investor Conferences

Noteworthy Thursday Option Activity: KLIC, HROW, SPB

Curious about the stocks that are showing activity before the opening bell on Thursday?

As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Stay updated with the stocks that are on the move in today's after-hours session.

Top movers in Wednesday's after hours session

Harrow Announces Third Quarter 2024 Financial Results

Harrow Launches Access and Affordability Program with Price Reductions for Branded Products

Harrow Announces Market Access Wins for VEVYE®

Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow’s Branded Eyecare Products

Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024

Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery

Notable Thursday Option Activity: HROW, NBR, EVGO

Harrow Relaunches TRIESENCE®

Harrow Announces Nashville Expansion

Harrow to Present at Three Investor Conferences in September in New York

Commit To Purchase Harrow At $27, Earn 22.2% Annualized Using Options

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to dive into the biggest pre-market stock movers on Thursday morning with all of the latest news this morning!

HROW Stock Earnings: Harrow Beats EPS, Misses Revenue for Q2 2024

HROW stock results show that Harrow beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

HROW Stock Earnings: Harrow Beats EPS, Misses Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Harrow (NASDAQ:HROW) just reported results for the second quarter of 2024.Harro...

Harrow Announces Second Quarter 2024 Financial Results

Noteworthy Tuesday Option Activity: GPRE, CPRI, HROW

Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024

Harrow to Attend 2024 ASRS Annual Meeting

Harrow Enters into 340B Prime Vendor Program Contract with Apexus™ for IHEEZO® and Other Key Harrow Products

Noteworthy Monday Option Activity: HUBS, HROW, SQ

HROW Stock Earnings: Harrow Beats EPS, Beats Revenue for Q2 2023

HROW stock results show that Harrow beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2023.

HROW Stock Earnings: Harrow Beats EPS, Beats Revenue for Q2 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Harrow (NASDAQ:HROW) just reported results for the second quarter of 2023.Harro...

Harrow Provides TRIESENCE® Relaunch Update

Noteworthy Friday Option Activity: HROW, OLLI, NKE

The Top 7 Growth Stocks to Buy and Hold Until 2030

These seven growth stocks look poised to outperform through 2030 and beyond with market-beating upside potential.